<DOC>
	<DOCNO>NCT02549196</DOCNO>
	<brief_summary>This Phase II , ascend dose study CPC-201 patient dementia Alzheimer 's type determine optimal dose titration schedule .</brief_summary>
	<brief_title>A Dose Titration Study CPC-201 Patients With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>This Phase II , ascend dose study CPC-201 patient dementia Alzheimer 's type determine optimal dose titration schedule . The study involve step wise cohort design two different patient population : Group 1 comprise patient treat low dose CPC-201 ( 5 10 mg/day ) ( give daily ) least 4 week prior Day1 . Group 2 consist patient never treat CPC-201 receive AChEI past 6 month . In study , CPC-201 dose increase weekly interval , accordance schedule give , first intolerable dose ( FID ) maximum allow dose ( MAD ) 60 mg/day . Cohort 1 1st week : 20mg 2nd week : 30mg 3rd week : 40mg 4th week : 50mg 5th week : 60mg Cohort 2* 1st week : 20mg 2nd week : 40mg 3rd week : 60mg Cohort 3* 1st week : 20mg 2nd week : 60mg * : The dose titration schedule Cohort 2 3 may alter base Cohort 1 result . Each cohort include approximately 6 patient CPC-201 ( Group 1 ) approximately 6 patient treated AchEI least 6 month ( Group 2 ) . Within cohort , Group 2 patient enrol least 3 Group 1 patient complete dose titration per protocol . Patients enrol Cohort 2 patient enrol Cohort 1 safely complete titration . Similary , patient enrol Cohort 3 , patient enrol Cohort 2 safely complete titration . Patients reach FID complete one week treatment CPC-201 60mg/day , two option . Option 1 : Patient allow immediately enter long term extension Maximum tolerate dose ( MTD ) MAD . Option 2 : Patients may choose enter long term extension , case Investigator decide whether patient discontinue high dose CPC-201 without down-titration , whetherCPC-201should downtitrated standard donepezil dose .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Signed Institutional Review Board ( IRB ) approve informed consent document 2 . Aged 50 89 year inclusive . 3 . Meeting diagnosis probable AD consistent : Revised National Institute AgingAlzheimer 's Disease Association ( NIAADA ) criteria Diagnostic Statistical Manual Mental Disorders ( DSM IV ) criterion . 4 . Mild severe severity ( MiniMental Status Exam [ MMSE ] score 7 24 inclusive ) . 5 . RosenModified Hachinski Ischemia Score ≤4 . 6 . Have suitable caregiver supervise athome administration study drug observe AEs . 7 . Patients treat donepezil 5 10 mg/day ( give daily ) least 4 week prior Day1 Population ( group ) 1 ; Patients never treat donepezil ( donepezil naïve ) receive AChEI past 6 month Population ( group ) 2 . 8 . Patients generally good health 1 . Women child bear potential . 2 . History presence seizure disorder . 3 . Current unstable peptic ulcer disease , urinary gastric retention ; asthma obstructive pulmonary disease . 4 . History presence bladder outflow obstruction , gastrointestinal obstructive disorder reduce GI motility , narrowangle glaucoma . 5 . History presence gastrointestinal , hepatic , renal disease , condition know interfere absorption , distribution , metabolism excretion drug . 6 . Renal hepatic dysfunction : Total Bilirubin : &gt; 1.5 x UNL AST : &gt; 2.5 x UNL ALT : &gt; 2.5 x UNL Serum Creatinine : &gt; 1.5 x UNL Creatinine Clearance : &lt; 30 mL/min ( calculate Cockcroft Gault equation ) 7 . History presence myasthenia . 8 . History family history Prolonged QT Syndrome . 9 . History unexplained syncope family history unexplained syncope sudden death . 10 . Myocardial infarction hospitalization congestive heart failure within 6 month . 11 . ECG finding : Complete Left Bundle Branch Block ; Ventricular pacing ; 2nd degree 3rd degree AV block ; Atrial fibrillation atrial flutter ; HR &lt; 45 &gt; 100 ; PR &gt; 220 msec ; QTcF &gt; 450 msec male , &gt; 470 msec female 12 . Known hypersensitivity donepezil , solifenacin related drug . 13 . History drug significant allergy . 14 . History substance abuse , know drug addiction , positive test drug abuse alcohol . 15 . Patients treat follow medication within 8 week screen Peripherally act anticholinergic ( drug treatment overactive bladder disorder ) , Psychoactive medication ( include antipsychotic , antidepressant , anxiolytic sedative hypnotic ) significant anticholinergic effect and/or believe affect cognitive function . Other medication acceptable , investigator discretion , dosage hold stable least 4 week prior screen throughout study . 16 . Patients consider unlikely cooperate study , and/or poor compliance anticipate investigator . 17 . Patients hospitalize within 4 week screen . 18 . Any clinically relevant acute chronic disease could interfere patient ' safety trial , expose undue risk , could interfere study objective . 19 . Patients participate another clinical trial investigational drug within previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>